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doi:10.1016/j.kjms.2010.12.001Abstract This account will give an overview and evaluation of the current advances in mass
spectrometry (MS)-based proteomics platforms and technology. A general review of some
background information concerning the application of these methods in the characterization
of molecular sizes and related protein expression profiles associated with different types of
cells under varied experimental conditions will be presented. It is intended to provide
a concise and succinct overview to those clinical researchers first exposed to this foremost
powerful methodology in modern life sciences of postgenomic era. Proteomic characteriza-
tion using highly sophisticated and expensive instrumentation of MS has been used to char-
acterize biological samples of complex protein mixtures with vastly different protein
structure and composition. These systems are then used to highlight the versatility and
potential of the MS-based proteomic strategies for facilitating protein expression analysis
of various disease-related organisms or tissues of interest. Major MS-based strategies re-
viewed herein include (1) matrix-assisted laser desorption ionization-MS and electron-spray
ionization proteomics; (2) one-dimensional or two-dimensional gel-based proteomics; (3)
gel-free shotgun proteomics in conjunction with liquid chromatography/tandem MS; (4)
Multiple reaction monitoring coupled tandem MS quantitative proteomics and; (5) Phospho-
proteomics based on immobilized metal affinity chromatography and liquid chromatography-
MS/MS.Research Resources and Development, Kaohsiung Medical University, Kaohsiung 807 or Institute of
, Taipei 115, Taiwan.
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掃瞄;
固定化金屬親和層析;
磷酸化蛋白質體學摘要 本評論文章將針對以質譜為基礎的蛋白質體學平台和技術的進展做一現況回顧和評價。文
章中將廣泛性回顧過去應用質譜方法,分析鑑定來自各種實驗條件下不同來源細胞的蛋白質分子大
小與整體蛋白質表現圖譜。本文章的目的是針對首次接觸到這個最重要且功能強大的質譜學新技
術方法的臨床研究人員,在後基因體時代應該具備的簡明基礎性蛋白質體學概念。運用高度複雜和
昂貴質譜儀器的蛋白質體鑑定技術,已被用於鑑定具有截然不同的結構和組成的複雜蛋白質混合物
生物樣品。這些顯著且具有多功能性和有潛力性的系統則已被有效應用於各種疾病相關的微生物
或組織的蛋白質體表達分析。這些以質譜為基礎的主要策略回顧包括：1.基質輔助雷射脫附游離
質譜和電灑游離的蛋白質體學 2.一維或二維凝膠電泳的蛋白質體學 3.無凝膠散彈槍法蛋白質體學
連接液相層析/串聯質譜（LC-MS/MS）4.多重反應監控掃瞄耦合串聯質譜（MS/MS-MRM）的定量
蛋白質體學 5.利用固定化金屬親和層析（IMAC）結合液相層析串聯質譜的磷酸化蛋白質體學。.
Copyright ª 2011, Elsevier Taiwan LLC. All rights reserved.Introduction and background
Modern clinical research is increasingly dependent on
evidence-based approach to biomedical research issues
related to human diseases with the advent of postgenomic
era and the completion of human genome sequences. There
comes next the functional genomics with its major em-
phasis on interactions between various genome-encoded
proteins. Subsequently, proteomics in the context of the
link between genes and proteins arose and evolved in
robust speed to become a major theme of central topics in
modern biomedical research.
Proteomes depict snapshots of protein compositions of
particular cells or tissues at defined time points. Through the
assistance of constantly increasing databases of complete
genomes from various model organisms, including human
and various submammalian species [1], proteomes of any
samples from some exotic biological sources can now be
analyzed at protein expression levels by various separation
methods coupled with mass spectrometry (MS) regarding
their protein identities in relation to other known protein
sequences deposited in various databanks. To date, proteo-
mics through the fast-evolving MS instrumentation has been
considered probably the most powerful and enlightening
breakthrough to be reckoned with in the research realm of
biomedical science. Recently, clinician scientists who have
gradually witnessed and appreciated the epoch-making
potential and impact of proteomics to biotechnology and
medicine in the foreseeable future began to use innovative
proteomic technology to clinical research especially on its
application to translational medicine. They are especially
interested in coupling the proteomics technology with bio-
informatics mining of human genome to unravel the related
molecular mechanisms of diseases. This has indeed engen-
dered the advent of clinical proteomics [2e12]. The newly
developed discipline would focus on effective clinical
monitoring and diagnosis of patients before and after
medical treatment and the prognosis and assessment during
the progress of disease treatment. This usually involves
several phases of proteomic study, that is, (1) biomarker
discovery; (2) biomarker verification; and finally (3) bio-
marker validation and clinical trial.
In this review, we have made an endeavor to summarize
and compare the following widely used workflow and me-
thodological strategies (Fig. 1) for the holistic proteomic
approach to characterize protein expression profiles of
various disease-related organisms or tissues of interest with
the aim of providing some application guidelines to clinicalresearchers interested in using clinical proteomics to trans-
lational medicine.
Proteomics strategies and platforms
Matrix-assisted laser desorption ionization-MS and
electron-spray ionization proteomics
Tanaka et al. [13] reported the first mass spectra for several
large proteinmolecules in 1988 by using nanometal particles-
assisted laser desorption, which started themacromolecular
characterization based onMSmeasurement for biomolecules
in ionized states. At about the same time, Karas and Hill-
enkamp [14] also developed matrix-assisted laser desorp-
tion/ionization (MALDI) MS for measurement of molecular
masses of different proteins with a time-of-flight (TOF) MS.
On the other hand, Fenn and co-workers [15] developed
electrospray ionization (ESI)-MS, which can also give soft
ionization of proteins. It is to be noted that MS developers
have tried to put major efforts in developing MSs for
macromolecule detection for many decades in vain mainly
because of the difficulty involved in the ionization of
macromolecules in vacuum to various ionized states.
Nowadays, MALDI and ESI MSs have overcome the ionization
problem to become the two major tools of choice for pro-
teomic study of complex biological systems especially
protein and peptide analysis, for which Tanaka and Fennwon
the Nobel Prize in 2002.
In general, the mass resolution and accuracy of a MALDI-
TOF MS is not high enough to give a nonambiguous identifi-
cation of a peptide with high confidence. Moreover, some
amino acid residues have similar or even identical molecular
weights (MWs). For example, the masses of both isomeric
amino acids, that is, isoleucine and leucine are 113.16
daltons (Da). The molecular masses of glutamine and lysine
are 128.131 and 128.174 Da, with difference between these
the two beingwithin 0.043 Da. Therefore, it is not feasible to
use MALDI-TOF for deriving protein sequences unambigu-
ously by measuring masses of various enzyme-digested
fragments to be analyzed in this type of MS instrument. On
the other hand, MALDI-TOF and its variant surface-enhanced
laser desorption/ionization(SELDI)-TOF possess unique
advantages of enabling a high-throughput analysis for pro-
teomic studies of multiple samples. These two MS platforms
have been commonly used to study expression proteomics
(i.e. protein profiling) of different types of tissues obtained
from the cohort patients. To date, MALDI ionization mecha-
nism is still not well understood. It can be essential to learn
Figure 1. Scheme of the current workflow and methodological strategies for proteomics application in biological science
and medicine. (Adapted and modified from: http://fenchurch.mc.vanderbilt.edu/lab/bmif310/2007/4-F-Liebler-Clinical-Proteo-
mics.pdf). MALDI-MSZmatrix-assisted laser desorption ionization mass spectrometer; MRMZmultiple reaction monitoring;
protein IDZ protein identification.
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biomolecular detection. Nevertheless, MALDI has been quite
efficient in detecting peptides (w1 fmole) but less success-
ful in oligonucleotide and polysaccharide especially when
the size is larger than 100,000 Da [1].
Collision-induced dissociation (CID) was introduced in
1968 to obtain structure information with a tandem MS
[16,17]. The first mass analyzer is used to determine the
mass spectrum of the sample and the second mass spec-
trum (denoted as MS/MS or MS2) is used to determine the
structure of selected peaks from the first mass spectrum by
a collision process with selected gas molecules. Sometimes,
higher orders of mass spectra (MSn) induced by CID can be
obtained to get more information on the identification of
biomolecular structures. To meet the demand of high-
quality proteomic studies, CID has been quickly adopted by
proteomic community to give more reliable determination
of sequences of peptides, which can be subsequently used
for more accurate protein determination.
Currently, there are two fundamental strategies for pro-
teomics study. One is bottom-upand the other is top-down. In
bottom-up approach, purified proteins or complex protein
mixtures are subjected to chemical or enzymatic cleavage
and the peptide products are usually separated by chroma-
tography followed by mass spectrometric analysis [18]. In
top-down proteomics, intact protein ions or large protein
fragments are subjected to gas-phase fragmentation for MS
analysis directly [19e21]. With top-down analysis, all post-
translational modifications (PTMs) will be subjected to anal-
ysis,whereas bottom-upanalysismay skip the fragmentswith
PTM. Becausemany fragmentation processes, such as CID are
not efficient for very large proteins (MW> 100,000 Da) in
routine operation, a true top-down strategy works only for
relatively small proteins. Some researchers also consideredMS analysis of peptides obtained from in situ digestion of
proteins after two-dimensional (2D) gel separation as a top-
down strategy (see below). With rapid progress in MS tech-
nology development and bioinformatics during the past few
years, proteomics study to identify various proteins in
complex protein mixtures isolated from tissues or cells of
interest is expected to become a routine high-throughput
exercise in the near future.
On the other hand, the special advantages for ESI as
compared with MALDI instrumentation include: (1) high
reproducibility: no crystallization process for sample prepa-
ration is involved; (2) high flexibility to attach to different
types of MS: the ESI source with lower mass-to-charge ratios
(m/z ratios) can be fitted to ion-trap, quadrupole, Fourier-
transform ion cyclotron resonance andTOF-MSbecauseof ESI’s
preference of multiple charged ions generated from various
biomolecules. The major disadvantages are (1) complex
spectra because of peaks frommultiply charged ions; (2) large
sample quantity: this disadvantage more or less disappears
after the introduction of nanospray [22]; (3) ESI cannot beused
for molecular imaging. The recent development of desorption
ESI nevertheless can compensate this defect, which can be
applied for molecular imaging but the space resolution is still
significantly worse than that obtained by MALDI [1].1D or 2D gel-based proteomics
In 1993, Henzel et al. [23] reported the first study related to
the global identification of proteins in biological samples
based on preseparation of protein mixture on 2D gel
electrophoresis (2-DE). The peptides were generated by in
situ tryptic digestion of proteins on polyacrylamide gels.
Masses of different peptides were analyzed by MALDI-TOF
4 S.-H. Chiou, C.-Y. WuMS. The mass spectral patterns of protein fragments
generated with trypsin digestion were then used for
comparison with those of previously known proteins
deposited in databanks to confirm peptides, which can be
used for identification of intact proteins (protein ID). This
study actually started and played a major role in the
popular and widespread proteomics analysis by combining
gel electrophoresis and MS.
Conventional protein separation and analysis by gel
electrophoresis started with one-dimensional poly-
acrylamide gel electrophoresis (1D gel or 1D PAGE). The
limitation for the analysis of complex protein mixtures is
that closely spaced protein bands tend to overlap, so that
any 1D gel separation method, such as sodium dodecyl
sulfate (SDS)-PAGE (PAGE in the denaturing agent SDS) can
only resolve only a relatively small number of proteins
(generally fewer than 50) [24]. In 1975, O’Farrell [25]
developed a new method of 2D PAGE to overcome the
shortcomings of 1D PAGE. Combining the features of two
different separation procedures with the first dimensional
separation being based on isoelectric points (pI) and the
second dimensional separation on molecular sizes of
protein components in the samples, 2D PAGE can resolve
more than 1,000 different proteins in the form of a 2D
polypeptide map [25]. In the first dimension, the sample of
interest is dissolved in a small volume of a solution con-
taining a non-ionic detergent (e.g. 0.5% (w/v) NP-40), the
denaturing reagent urea, and reducing agents, such as
dithiothreitol or mercaptoethanol. This sample buffer
solution can dissolve and dissociate most of the proteins
(with some exceptions) from any tissues without changing
their intrinsic charges. Then the polypeptide mixture is
separated by the principle of isoelectric focusing. In the
second step, the narrow gel containing the separated
proteins is soaked in SDS and the proteins are further
fractionated according to the size by SDS-PAGE on a slab
gel. Each polypeptide chain nowmigrates as a discrete spot
on the gel according to its MW. The only proteins left
unresolved will be those that have both an identical size
and an identical pI, a relatively rare situation. There has
been an increasing emphasis on the separation and char-
acterization of polypeptides by 2D PAGE in recent years,
which has been claimed to be the most sensitive and high-
resolutionmethod for the analysis of protein composition in
any cell extract or protein mixture. The second dimension
of SDS-PAGE can usually be run in gradient gels [24] to even
improve the resolution. For higher sensitivity, cell extract
or protein mixture can be labeled with a radioisotope
before running 2D PAGE. Up to 2,000 individual polypeptide
chains can be resolved on a single 2D gel, enough to account
for most of the proteins in a bacterium. One reason for the
popularity of this method is that because the two dimen-
sions separate proteins on the basis of two independent
parameters (their pIs in one dimension and protein subunit
sizes in the other), one usually obtains an excellent reso-
lution of even very complex protein mixtures. A 2-DE was
thus considered as the method of choice, as it could afford
a high throughput and relatively high-resolution analytical
tool to resolve and separate a mixture of thousands of
protein species with different charge and size properties
[24]. However, the serious drawback of low sensitivity can
be attributed to the fact that the maximal numbers ofseveral thousands of spots resolved and analyzed by 2D is
still relatively small as compared with the whole genome-
encoded functional proteins of about 20,000e30,000
proteins, especially being underrepresentative of some
special classes of proteins, such as the extremely basic or
acidic groups of proteins, some low-abundance transcrip-
tion factors, and membrane proteins [24,26,27] because of
the low solubility of these classes of proteins in the first
dimensional isoelectric focusing gel. Currently, 1-DE
instead of 2-DE in the presence of the most effective
denaturing agent of SDS is more often used for proteomic
analysis of samples of poor solubility. A proteomic sample is
first separated and resolved in the 1D gel (Fig. 2A). The
proteins can usually be separated into at least 5 to more
than 10 different blocks depending on the complexity of the
proteomic samples. Then the separated protein bands are
subjected to digestion with trypsin. The products are
subsequently fed into a liquid chromatograph MS (LC-MS or
LC-MS/MS) for protein ID. Fig. 2A and B showed the repre-
sentative 1DE and 2DE of protein mixtures of human and
porcine eye lenses under dissociating conditions in the
presence of SDS for the resolution of complex protein
components. These were carried out on polyacrylamide
gels using slab gel instead of rod gel systems. It can be seen
that 1D gel being less tedious and time consuming than 2D
gel still affords a respectable protein separation and
protein ID analysis similar to that of 2D gel.
Gel-free shotgun proteomics in conjunction with
LC-tandem MS (LC-MS/MS)
The recent explosion in available genomic sequence infor-
mation is providing a useful sequence infrastructure for
clinical proteomics. A major aspect of various proteomics
strategies is the protein ID using analytical “fingerprints” or
peptide mass fingerprinting (PMF) generated by digestion of
proteins with specific enzymes, such as trypsin, followed by
tandem mass (MS/MS) spectrometry, from which MS/MS
spectra of peptide fragments can then be used for
comparison and search in available sequence databanks.
The mixture of enzyme-digested proteins or peptides
can usually be separated by multidimensional LC (MDLC)
and analyzed by a tandem MS. Various MS/MS spectra
can be algorithmically compared with predicted peptide
spectra from sequence databases to identify the respective
proteins. The digestion of intact protein or peptide
mixtures with various enzymes of different specificities
followed by the direct analysis of the resulting peptides by
high-resolution LCs coupled with tandem MS/MS has facili-
tated the so-called “shotgun” strategy for the identification
of protein mixtures without the need for prior sample
fractionation based on 1D or 2D gels (gel-free proteomics).
By combining with the recent development of capillary
MDLC, this approach is now capable of characterizing
proteins directly from entire cell lysates [28e31]. In
shotgun proteomics, MDLC is a necessity to reduce sample
complexity and increase dynamic range of protein identi-
fication. For some years shotgun proteomics has been the
method of choice for analysis of complex samples because
of its ease of automation, high throughput, and sensitivity.
Shotgun proteomic approach involving nano-LC quadrupole-
TOF MS has also been especially attractive for efficient
Figure 2. Analysis of lens proteins by 1-DE and 2-DE gel electrophoresis. (A) Analysis of lens proteins from normal human lens
without cataract by SDS-PAGE. As shown in the left panel, a total of 10 mg lens proteins were separated and resolved in 12.5% SDS-
PAGE and stained with Coomassie brilliant blue R-250. N, normal person; P, cataract patient. In the right panel, protein bands
(indicated by arrows) were in-gel digested with trypsin, followed by LC-MS/MS to find protein ID based on PMF of digested proteins.
(B) Two-DE gel patterns of porcine lens proteins. 100 mg total protein was loaded onto immobilized pH gradient (IPG) gel strips (pH
3e10 nonlinear, 13 cm). For the 1D separation, IEF was carried out at 300e8,000 V for 16 hour. After IEF, the IPG strips were
equilibrated in SDS-urea buffer and placed onto the 2D SDS-PAGE. After electrophoresis, the gels were fixed in 10% methanol and 7%
acetic acid and stained by Sypro-Ruby. Protein spots marked by No. 1e20 on the map were further identified by nano LC-MS/MS.
The result is representative of three independent experiments. (Courtesy of Molecular Vision Press; [63]). 1-DEZ one-dimensional
gel electrophoresis; 2-DEZ two-dimensional gel electrophoresis; IEFZ isoelectric focusing; LC-MSZ liquid chromatography
coupled tandem mass spectrometry; pIZ isoelectric points; PMFZ peptide mass fingerprinting; SDS-PAGEZ sodium dodecyl
sulfate-polyacrylamide gel electrophoresis.
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mass spectrometric methods are being developed along the
line that not only identifies proteins in a mixture but also
compares the relative levels of protein expression between
two different samples, that is, quantitative proteomics.
Quantitative proteomics
To date, the current bottom-up proteomic approach to find
protein ID in various biological samples gradually becomes
a routine practice. Now the major challenge lies in quanti-
tative measurements for different proteins in unknown
samples of interest. Biomarker discovery is especially de-
pendent on the accurate quantitative difference between
normal and diseased samples. In the search for disease-
associated protein determinants, reproducible and quanti-
tative proteomic analysis remains a vital analytical part in
the study of the translational effects of various protein
biomarkers in regulating cellular activity and function.
Therefore, quantitative determination of each individual
protein deserves more efforts. On the other hand, the
extension of dynamic range tomeasure ultra-lowquantity of
proteins inside a proteomic sample remains a high priority
and a great demand. Currently, there are two different
approaches to quantitative proteomics. One is strictly based
on mass spectra from MS/MS without labeling and the other
relies on the labeling methodology.
Label-free quantitative proteomics
Label-free approach for quantitative proteomics is more
attractive because it can reduce the contaminant species
during the labeling process before proteomic analysis with
high sensitivity. Nevertheless, the entire process for proteo-
mic analysis without a quantitative labeling tag is quite
complex. It is also very difficult to assure quality control on
every purification and analytical step in different laborato-
ries or different personnel from the same laboratory. For
example, sample collection can be a big concern. It is known
that degradation of proteins/peptides can occur without
proper precaution. Ionization efficiency for a selected
protein under a different environment can be quite different
in both MALDI and ESI ionization processes. It is well known
that ionization is a strong function of acidity in the sample.
When LC-MS or MDLC-MS on-line analysis is used, the quantity
of proteins/peptides to be analyzed can also depend on the
time protein/peptide is eluted for MS analysis. Owing to the
great advantages of simplicity and time saving, tremendous
effort has been placed on developing label-free quantitative
proteomics. In general, for label-free LC-MS experiments to
achieve quantitative determination, peptide ion intensity
counting and spectral counting have been used extensively.
At present, there are still controversies over the reliability of
label-free quantitative analysis. It is noteworthy that quan-
titative determination between two samples cannot be just
based on qualitative protein ID analysis without a dedicated
proteomic analysis platform to do data analysis. Heavy
participationof bioinformatics softwareanalysis iswarranted
for the future success of label-free quantitative analysis.
Label-based quantitative proteomics
Isotopic-coded affinity tag
The basic principle of Isotopic-coded affinity tag (ICAT) [32]
relies on the protein thiol-specific reagents. It consists ofthree major steps: (1) a special affinity tag is used to react
with cysteine residues in a protein; (2) labeled peptides are
obtained from the enzymatic digestion of labeled proteins;
and (3) labeled peptides are separated by LC or MDLC fol-
lowed by MS analysis for relative quantitative measure-
ments. ICAT is often used to measure the relative protein
abundance between two samples, such as tissues from
a healthy person and a patient. However, the analysis is
usually long and expensive because of high costs of isotopic
labeling reagents.
Isobaric tags for relative and absolute quantitation
The quantitation strategy for isobaric tags for relative and
absolute quantitation (iTRAQ) labeling [33] of multiplexed
sets of experiments is commonly based on a set of four
isobaric reagents, each of which comprises three groups:
reporter (mass from 114 to 117 Da), balance (mass from 28
to 31 Da), and reactive groups. After cell lysis, reduction/
alkylation, and protein digestion, the peptides in four
states are separately labeled on N-terminal and internal
lysine residues by the reactive group of iTRAQ. Each labeled
peptide appears at the same mass in a MS scan. During the
fragmentation in the MS, the label dissociates and releases
the reporter group as a singly charged ion of masses 114,
115, 116, or 117 Da, respectively. Relative intensity of
these peaks indicates the contribution of each sample to
total peptide intensity and can provide the information on
the relative abundance. The labeled peptides are then
combined and analyzed by MDLC and MS. The multiplexed
protein quantitation capability of the iTRAQ strategy
permits simultaneous comparison of samples of different
cell states and disease specimens. This advantage can be
applied to a comparative study on the temporal and/or
spatial distribution of proteins in cells. iTRAQ can be used
to simultaneously label and analyze up to four different
samples. Absolute quantitative measurement of a specific
protein can also be achieved by iTRAQ. This involves
comparing peptides from a target protein to a known
amount of labeled standard peptide added to the sample.
Stable isotope labeling with amino acids in cell culture
Stable isotope labeling with amino acids in cell culture
(SILAC) was developed by Ong et al. [34] to detect proteomic
differences between two cell samples. One of the cultured
cell populations is fed with normal amino acids. In contrast,
second cell population is fed with amino acids labeled with
stable (nonradioactive) isotopes. For example, the medium
cancontain arginine labeledwith six 13C insteadof thenormal
12C. During the cell growing period, they incorporate arginine
into all of their proteins. Therefore, all heavy arginine-con-
taining peptides are heavier than their normal counterparts
by 6 Da. Pairs of chemically identical peptides of different
stable isotope composition can be clearly distinguished
becauseof theirmass difference.The ratio of peak intensities
for such peptide pairs can accurately reflect the population
ratio for the two proteins. SILAC is becoming a powerful tool
to study cell signaling [35e37].
H2O
18 labeling
Both ICAT and iTRAQ involve specific reagents for labeling.
Another simple and inexpensive approach is by H2O
18 labeling
during the process of trypsin digestion. One or two O18 can be
incorporated into the carboxyl group of peptides. Mass peaks
with M plus 2 and 4 can be expected [38,39]. This approach
provides a very simple method for quantitative
Clinical proteomics 7measurement. However, analysis confusion may arise
because of the interference peaks by other peptides in the
digested buffer solutions.
Analysis andquantitation of 1D- or 2D-gel protein profiles
Before the development of PMF, proteomic studies were
usually pursued by 1-DE or 2-DE. The visible bands or spots in
1D or 2D gel are based on isotope radioactivity labeling or
staining with silver stain or Coomassie brilliant blue dye
methods [24]. A 2-DE gel is difficult to do automatic data
analysis when a high number of 2D gel pictures need to be
analyzed. Nevertheless, it is still broadly used in most bio-
logical laboratories when complex protein mixtures of
a specific tissue sample of interest need to be analyzed based
on the global distribution of protein expression profile at
a particular developmental stage. Each visible band or spot
may represent one or a few proteins. To identify the proteins
in the specific band or spot, the gel can be cut out for enzy-
matic digestion followed by PMF spectrometry. When two 2D
gel pictures are compared to single out the clear differences
of corresponding proteins, 2-DE is a convenient tool to find
out different proteins with characteristic PMF used for
protein ID (Fig. 3). Analysis of 2D gels in its simplest form can
be carried out by superimposing onephotographic image over
another. However, better and more accurate results can
usually be obtained by computer analysis of the gels.Figure 3. Protein expression profile in 2D gel of H. pylori
cultured in BHI culture media. 250 mg of total proteins from
lysates of H. pylori cells were loaded on IPG gel strips (pH
3e10, 13 cm) for the first-dimensional separation (IEF) fol-
lowed by SDS-PAGE on the second dimension. Protein spots
marked by No. 1e3 on the map were further identified by nano
LC-MS/MS to be alkylhydroperoxide reductase (HP-AhpC),
nonheme-iron ferritin (HP-ferritin), and urease B. The result is
representative of three independent experiments. (Courtesy of
Japanese Biochemical Society; [80]). BHIZ brain heart infu-
sion; H. pyloriZ Heliobacter pylori; IEFZ isoelectric focusing;
IPGZ immobilized pH gradient; LC-MSZ liquid chromatog-
raphy coupled tandem mass spectrometry; SDS-PAGEZ sodium
dodecyl sulfate-polyacrylamide gel electrophoresis.Reproducible gels from which data can be collected on
several hundred and perhaps over a thousand proteins from
a single gel of one sample can now be analyzed automatically
by scanning (gel scanner) and computer analysis with various
versions of computer algorithms for data collection and
analysis [40]. The systemmust be able to compare andmatch
up patterns from several gels to allow accurate identification
of spots for quantitative analysis. With the recent advent of
powerful personal computers and the associated analysis
softwares, it has become increasingly obvious that 2D protein
gels can now be satisfactorily and reproducibly analyzed if
they are digitized and the features of protein data displayed
on the gels abstracted using an automated system. A 1D SDS-
PAGE (Fig. 2A) is especially more straightforward and simpler
than any previous method of protein analysis principally
because it can be used to separate any proteins regardless of
their inherent solubility in aqueous solution.
Although other physical methods can also give rise to the
same information of molecular mass estimation afforded by
SDS-PAGE, they lack the simplicity in the procedure and
short time required for SDS-PAGE. Most noteworthy is that
SDS-PAGE is a relatively simple and reproducible technique,
which requires only micrograms of samples yet is capable of
very high resolution as it can separate proteins differing in
mobility by as little as 1% (a difference in molecular mass of
1 kDa for a 100 kDa protein), inferior only to the above-
mentionedMSmethodology. It should be kept inmind that in
great contrast to current state-of-the-art MS, themolecular
mass and quantity estimation by 1-DE or 2-DE is basically
a relative method, which requires that molecular mass
marker proteins be included with each gel run and a stan-
dard curve drawn for that particular gel under the specified
conditions.
Comments on quantitative proteomics
All the above methods including ICAT, iTRAQ, SILAC, H2O
18,
and 2D gel are in general designed for relative quantitative
proteomic analysis and comparison of selected proteins
among different pair-wise samples under some specified
conditions. In contrast, methods for absolute quantitative
protein determination are more desirable than the relative
methods from the quantitative aspects of proteomic
approaches. Proteomics based on absolute quantitative
analysis is aimed to measure the absolute level of protein
biomarkers using a characteristic peptide unique to the
studied protein. Absolute quantification and stable isotope
standards and capture by antipeptide antibodies (SISCAPA)
are two reported approaches for absolute quantitation
[41e44]. For absolute quantification, peptides generated
from specific enzymatic digestions are synthesized with
heavy isotopes. A known quantity of the synthesized
peptides with known molecular masses was added to pro-
teomic samples as internal standards for intensity com-
parison to determine the quantities of the studied proteins.
For SISCAPA, antipeptide antibodies immobilized on novel
nanoaffinity columns are used to concentrate and enrich
specific peptides along with stable isotope-labeled internal
standard of the same sequences. On elution from the
antipeptide antibody affinity column, ESI-MS is then used to
determine the quantities of peptides by comparison of the
signals from the peptides with those of the corresponding
stable isotope-labeled internal standards [45].
Figure 4. Identification of in vivo oxidized products of AhpC from H. pylori by LC-MS/MS. (A) The spectra of the digested
peptides from oxidized HP-AhpC as analyzed and plotted by MASCOT database search program. The MS/MS fragmentation pattern
shows the presence of the Cys49-containing peptide DFTFVCPTEIIAFDK, in which Cys49-SH at the catalytic site has been converted
to Cys49-SO2H. (B) The spectra of the digested peptides from oxidized HP-AhpC as analyzed and plotted by MASCOT program. The
MS/MS fragmentation pattern shows the presence of the Cys49-containing peptide DFTFVCPTEIIAFDK, in which Cys49-SH at the
catalytic site has been converted to Cys49-SO3H. (Courtesy of Japanese Biochemical Society; [79]). H. pyloriZ Heliobacter pylori;
LC-MSZ liquid chromatography coupled tandem mass spectrometry.
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quantitative proteomics
Quantitative targeted proteomics focusing on multiple
reaction monitoring-MS (MRM-MS) methodologies has taken
front stage in the proteomics research recently, especially
being frequently applied to the verification of global pro-
teomics data, the discovery of lower abundance proteins,
protein PTMs, and biomarker discovery [46]. As an older
methodology used for small molecule analysis, MRM-MS has
been adapted as the next methodological advance to
address previously challenging issues in global proteomics
experimentation, namely dynamic range, identification of
PTMs, and sensitivity/selectivity of measurements. These
developments have shown that targeted MRM analysis on
nonredundant peptides of conventional MS/MS data of
potential biomarkers can provide more exact quantification
of homologous proteins. The methodology has facilitated
the transition from routine biomarker-discovery proteomics
to quantitative targeted-proteomics analysis, further
allowing us to identify and verify more low-abundance
potential biomarkers.MRM is the extended version of Selected Reaction Moni-
toring (SRM), which arose as a technology to complement the
discovery capabilities of shotgun proteomic strategies by its
unique capability for reliable quantification of biomolecules
(or termed analytes) present at low abundance in complex
mixtures [47]. SRM exploits the unique capabilities of triple
quadrupole MS for quantitative analysis, which is ideally
suited to address a major proteomic challenge in systems
biology for the accurate quantification of some specific sets
of proteins spanning the whole range of cellular proteomes
from different samples of evolutionarily related organisms.
In SRM, the first and the third quadrupoles act as filters
to specifically select predefined m/z values corresponding
to the peptide ion and a specific fragment ion of the
peptide, whereas the second quadrupole serves as collision
cell. Several such transitions from precursor peptide to
their fragment ion pairs are monitored over time, yielding
a set of chromatographic traces with the retention time and
signal intensity for a specific transition as coordinates. The
two levels of mass selection by two quadrupoles with
narrow mass windows result in a high selectivity, as coe-
luting background ions are filtered out very effectively.
Figure 5. The representative tandem mass spectra of the phosphorylated peptide 12RPFFPFHS*PS*R22. (A) MS/MS spectrum of the
peptide phosphorylated at Ser-19. (B) MS/MS spectrum of the peptide phosphorylated at Ser-21. The purified phosphopeptides
samples less than 1 mg each from IMAC were first injected into a 2 cm 180 mm capillary trap column followed by LC-MS/MS and
spectra collection. Based on the tandem mass spectra of the modified peptide 12RPFFPFHS*PS*R22 as compared with the original
peptide, it can be deduced that both Ser-19 and Ser-21 are phosphorylated. The location of the peptide fragment within the
protein is shown by the residue numbers 12 and 22 for the N- and C-terminus of the phosphorylated peptide sequence. Identified b-
and y-ion fragment series are marked by the numbers above and under the peptide sequence, respectively. The putative site of
phosphorylation is indicated by the P* in front of serine residues. The mass signals were amplified by fivefold except the ion with
the highest intensity. (Courtesy of Molecular Vision Press; [63]). IMACZ immobilized metal affinity chromatography; LC-MSZ liquid
chromatography coupled tandem mass spectrometry.
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spectra are recorded in triple quadrupole-based SRM anal-
ysis. The nonscanning nature of this mode of operation
translates into an increased sensitivity by one or two orders
of magnitude compared with conventional “full scan”
techniques. In addition, it results in a linear response over
a wide dynamic range up to five orders of magnitude. This
enables the detection of low-abundance proteins in highly
complex mixtures, which is crucial for systematic quanti-
tative studies of biomolecular samples.
It is also important to note that SRM and MRM have been
successfully applied to a variety of biological applications,
including robust quantitative proteomic analysis of cellular
signaling networks [48], quantification of DNA adducts
purified from tissue [49], and detection of doping
substances in human urine and plasma [50e53]. To date,the use of SRM and MRM in proteomics is less widespread,
although MRM has been used to quantify protein expression
[54], to find protein biomarkers for disease severity in
rheumatoid arthritis [55], and to detect and quantify
protein phosphorylation profiles [48,56e58].Phosphoproteomics based on immobilized metal
affinity chromatography and LC-MS/MS
PTM of genome-encoded polypeptides is prevalent (about
10%e50% of proteins are phosphorylated) in various biolog-
ical systems, which commonly includes acetylation, meth-
ylation, deamidation, glycosylation, phosphorylation, and
various proteolytic truncations [59e62]. Up to now, most
proteomics studies on the analysis of PTM are limited to
Figure 6. The percent distribution of phosphorylated sites identified by gel-free IMAC enriched phosphopeptide and LC-MS/MS
analysis. (A) Proportion of the proteins with phosphorylation in total lens extract. (B) Distribution of in vivo phosphorylation sites in
aB-crystallin. (C) Distribution of in vivo phosphorylation sites in bB1-crystallin. (D) Distribution of in vivo phosphorylation sites in
aA-crystallin. The three most abundantly phosphorylated proteins (%) in the lens are shown under the identified phosphoproteins
in AeD. It is noted that phosphorylated sites of aA-crystallin are more evenly distributed along the protein molecule than aB- and
bB1-crystallins, which show the predominant phosphorylation sites at residues 59 and 189 in aB- and bB1-crystallins, respectively.
(Courtesy of Molecular Vision Press; [63]). IMACZ immobilized metal affinity chromatography; LC-MSZ liquid chromatography
coupled tandem mass spectrometry.
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known that phosphorylation is most noteworthy for playing
a major role in the regulation of various biosignaling path-
ways [61], which may include ion transport, enzyme activa-
tion or inhibition, protein degradation, cancer development,
and aging. Phosphorylated proteomics has been used to
quantify dynamic changes in phosphorylated proteins over
time. Herein, we present our data on quantitative phos-
phoproteomics using shotgun proteomic approach coupled
with immobilized metal affinity chromatography (IMAC) and
LC-MS/MS (Figs. 4 and 5). Identification of protein phos-
phorylation and its exact locations in proteins or enzymes of
interest are always considered as a preeminent and
nontrivial task in the conventional mechanistic and func-
tional study of various cellular proteins. Mainly attributable
to the advent of emerging proteomics, the investigation of
protein phosphorylation has recently become less tedious
and more amendable to routine analysis [28e30]. The
common strategy of most conventional proteomic
approaches to the identification of phosphorylated proteins
rests in the PMF of proteins under study, which can be used asan identification tag to search the corresponding identical or
highly homologous sequence fragment patterns in protein
sequence databanks. Such fingerprints usually come from
the tandem mass spectra of peptides generated from
proteolytic digestion of proteins of interest.
As mentioned above, the serious drawback of low
sensitivity and underrepresentation for some special
classes of proteins, such as the extremely basic or acidic
groups of proteins and membrane proteins, by using gel-
based 1D or 2D gel proteomics [24e27] necessitated the
development of more sensitive labeling methods, such as
stable isotopic labeling [34e37], in conjunction with
multidimensional LC-MS/MS analysis. Methodologies to date
still do not exist for conducting a routine and reliable high-
throughput analysis of proteome-wide changes in the
phosphorylation of proteins. In our pilot study, phosphory-
lated and nonphosphorylated lens proteins from porcine
eye lenses were first identified by gel-based 2D gel protein
fractionation and separately by gel-free enrichment of
phosphopeptides from trypsin-digested protein mixture on
IMAC followed by LC-MS/MS. Based on our results of the
Clinical proteomics 11comparison and evaluation of two different protocols of
proteomic approaches, we conclude that gel-free IMAC
phosphopeptide enrichment, coupled with LC-MS/MS anal-
ysis, is now capable of identification of phosphorylated
sites from the whole lens extract, effectively circumventing
the need for prior protein separation by 2-DE. Our results
clearly showed that two subunits of a-crystallin, aA-crys-
tallin, and aB-crystallin (Fig. 2B), as well as other lens
crystallins and noncrystallin cellular proteins, such as b-
enolase, heat shock protein b-1 (HSP27), and glucose-6-
phosphate isomerase, were found to be phosphorylated in
vivo at specific sites. Moreover, aA- and aB-crystallins were
found to be the most abundantly phosphorylated proteins in
porcine lenses, being extensively phosphorylated on serine
or threonine but not on tyrosine residues. Technically, the
gel-free IMAC method facilitates direct site-specific iden-
tification of phosphorylation residues in lens proteins.
Moreover, the improved strategy using gel-free phospho-
proteomics analysis affords a more effective and simplistic
method for the determination of in vivo phosphorylation
sites than the conventional 2-DE preseparation of protein
mixture. Therefore, the adaptation of quantitative shotgun
proteomics in protein phosphorylation study (Fig. 6, [63])
proves to be very useful and form a firm basis for the future
comprehensive analysis of other PTM in our lens protein
system in terms of aging and various diseased states.
Conclusion
In the postgenomic era, the development of technologies for
systematic, qualitative, and especially quantitative pro-
teome analysis of biological samples from cells or tissues of
biological systems especially humans has become an
important focus of biomedical research. MS-based analytical
methodology is now widely used for screening for inborn
errors of metabolism [64,65], study of different types of
cancer [66e68], viral or bacterial infections [69,70], car-
diomyopathic heart disease [71], neurodegenerative disor-
ders, such as Alzheimer’s [72] or Huntington’s [73] diseases,
and even some applications in forensic medicine [74,75]. In
our study of biomarkers related to Helicobacter pylori-
associated gastroduodenal diseases by a proteomic
approach (Figs. 3 and 4), we have identified several crucial
pathogenesis-related proteins that have diagnostic and
prognostic potential. Among them, antibodies to GroEs and
AhpC of H. pylori [76,77] could probably be used for identi-
fication of patients who are at high risk of disease compli-
cations after H. pylori infection. Indeed, proteomics
technology has been proved to be a tremendously powerful
tool for simultaneously determining the presence of proteins
and protein variation on a large scale in biological samples
collected from H. pylori-infected patients. This newly
developed and fast-evolving methodological advance has
provided unprecedented opportunity to survey a cell’s
translational landscape in a global and comprehensive way
to allow in-depth analyses of host and pathogen interaction.
Using this MS-based proteomics platform and taking advan-
tage of complete sequences for both the H. pylori and the
human genomes in various databases, some promising
results and important information have been derived
[80,79,78,81]. On the other hand, the salient application ofimproved shotgun quantitative phosphoproteomics led to
the effective and facile determination of previously unre-
ported in vivo phosphorylation sites (Fig. 6) in our study of
whole tissue extract from various animal eye lenses. The
methodology is certainly to play amajor role to elucidate the
biological significance of phosphorylation in relation to
various biosignaling pathways [82,83].
Regarding the recent development of quantitative clin-
ical proteomics with its main focus on “biomarker
discovery,” more than 20,000 protein or peptide potential
biomarkers have been revealed for cancer and other
diseases in the literature. However, only a few candidates
have been verified and validated by the United States Food
and Drug Administration, in fact only seven protein
biomarkers being approved between 2003 and 2008 [84,85].
The reason for this low success rate for verified and validated
biomarkers is that only a small number of the reported
candidate biomarkers have passed verification stage
[86e88], and even fewer have been validated [89,90], which
generally requires measuring the proposed biomarker in
even larger cohorts of patients. On the practical side, to
date, a complete proteomic analysis of one sample with the
best MS instrumentation still needs at least one whole day.
For a biomarker discovery aiming for a particular disease, it
may need less than 10 samples (i.e. numbers of normal and
patients), whereas biomarker verification can require
100e1,000 samples and biomarker validation requires even
larger numbers of samples (thousands to tens of thousands)
to be certain that the target molecule is a true biomarker of
the disease and the “false-positive” rate of the developed
assay can be estimated [88]. Therefore, it will take at least
one whole year to accomplish such a large-scale screening
and survey. Taking into a further account of analysis for
phosphoproteomics, glycoproteomics, metabolomics, and
so forth, it should take even longer to finish a comprehensive
study for a validated biomarker. It is clear that innovative
new technologies need to be developed to overcome this
time limitation.
Future perspectives
Although we have witnessed tremendous progress in proteo-
mics for the past decade (since the year of 2000), several
major concerns and challenges need to be addressed tomake
a further transition to health and disease-related clinical
proteomics in the future. At present, the bottlenecked
obstacles are (1) the lack of established and routineMS-based
analytical technology for PTM; (2) limited MS sensitivity, low
dynamic ranges, and low resolution for biomolecules
measured at high m/z ratios of greater than 100,000 for most
MS instruments other than MALDI-TOF; and (3) undesirable
long analysis time needed for clinical biomarker verification
and validation. It is true that pre-MS analysis methodologies,
such as electrophoresis and high-performance liquid chro-
matography are also time consuming. ESI-MS also takes more
time than MALDI. An improved MALDI-TOF technology with
the mass resolution reaching that of a Fourier-transform ion
cyclotron or ion trap MS would be a better MS for a more
satisfactory and high-throughput analysis in clinical proteo-
mics. An automated, high-throughput, and multiplexed
methodusingMRMcoupledMS-basedquantitativeproteomics
12 S.-H. Chiou, C.-Y. Wu(MS-MRM or MS/MS-MRM) has been proposed, which is very
promising for clinical trials of protein/peptide biomarkers
[91,92].
Finally, the ultimate goal for proteomic researchers is to
be able to do single cell proteomics especially for cancer or
stem cell research. Recently, single cell trapping and
measurement of the mass of a single cell have been success-
fully demonstrated [93e95]. It should be feasible to break up
the trapped cell and release small and large biomolecules for
MS-based ionization and fragmentation, which may result
in unraveling the detailed mechanistic pathways for the
metabolic transition of macromolecules to small organic
component molecules.
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